The success of this approach in a preclinical setting was ascribed to IDH1-mutant gliomas having a CpG island methylator phenotype (CIMP) characterized by the robust and widespread methylation of CpG islands [121]. The gene discussed is IDH1; the disease is central nervous system cancer.